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In 2011 and 2014, Frye et al [1] and Tralau-Stewart et al [2] published an account of academic 
screening undertakings within the USA and UK, respectively. Tralau-Stewart et al observed that 
academic screening within the UK is comparable to the USA with regard to primary therapeutic 
focus, (with cancer, infectious disease and cardiovascular disease constituting the most highly 
prioritised therapeutic indications) and areas of unmet medical need. Parallels were also drawn 
between the motivational drivers and annual operating costs. However, regarding infrastructure, it 
was reported that most drug discovery programmes (DDPs) in academic screening groups (ASGs) 
within the UK were conducted within a ‘traditional’ research group (i.e. a team of postdocs, Ph.D. 
students and technicians led by a single Principal Investigator), with only 13% operating within a 
drug discovery-dedicated centre. The most surprising finding was that “access to HTS facilities and 
associated compound libraries was not reported by any UK group” [2]. The authors were clear to 
state that responses provided a “snapshot” of academic research at the time of surveying (2013), 
and not a comprehensive analysis. However, we feel centre-led ASGs and industry standard DDPs 
conducted within an academic environment in the UK has been grossly understated. 
Academic Screening Groups and Drug Discovery Units within the UK 
We have identified 23 dedicated drug discovery units/facilities across the United Kingdom (Table 1), 
each applying the drug discovery tenet to different clinical indications within a 
pharmaceutical/biotechnology infrastructure. These facilities have a range of operational 
frameworks: some are academic facilities operated by universities with several sources of funding, 
several are operated by charitable organisations, while others are industrial facilities sited on or near 
academic campuses. The common theme linking them is they are all open-access drug discovery 
facilities, accessible by UK-wide academic groups and each facility employs some personnel from 
academia thereby strengthening links to the UK academic community. These groups may therefore 
be better referred to collectively as academic and not-for-profit screening groups. However, for 
simplicity’s sake, we will hereon refer to them as ASGs. 
The scale of undertaking and the resourcing of these groups vary according to the objectives of each 
facility. Some groups provide dedicated support for distinct aspects of the drug discovery pipeline, 
for example target discovery or identification of chemical starting points for nominated disease 
indications, and are resourced with the relevant expertise/technical knowledge.  At least six ASGs 
conduct industry-standard drug discovery resourced largely by professionals with substantial 
industrial experience and incorporate extensive in-house medicinal chemistry expertise and DMPK 
resource. 
All of the identified groups reported the execution of multiple HTSs in the past year (Table 1). They 
actively pursue primary screen hits for further validation or drug development, and regularly publish 
their results in peer reviewed scientific journals. Additionally, we found that all of the groups employ 
industry standard liquid handling/readout instruments, and have research staff dedicated to each 
step of the drug discovery pipeline (i.e. compound management, assay development/screening, data 
analysis, etc.) suggesting their facilities are well equipped in both instrumentation and personnel. 
These facilities represent a major investment in UK drug discovery research. The similarity in facility 
numbers between the UK and the USA, highlights a clear commitment within the UK to provide the 
infrastructure necessary to support academic screening. 
Funding and Collaboration 
Currently, the majority of funding for the major UK ASGs is provided by the UK government with 
considerable support coming from universities, UK and international charitable organizations 
(Cancer Research UK supports programs at 5 of the 23 facilities), and the UK Medical Research 
Council.  In addition to governmental and charitable funding streams, we have recently experienced 
a paradigm shift in the perception of academic screening by the industrial sector. Pharmaceutical 
companies now recognise the potential of academic alliances and have entered into partnerships 
with UK ASGs. Collaborative efforts to address a broad range of disease areas (Table 1) are 
underway, through provision of well characterised compound collections (GSK and Pfizer) and/or 
engaging closely with academic partners to enhance their own drug discovery capacity.  Notable 
examples include AstraZeneca’s Open Innovation Initiative, GSK’s Centre for Therapeutic Target 
Validation (CTTV), and the Eisai-UCL collaborative drug discovery alliance. These partnerships are 
evidence that the UK academic screening community is held in high esteem by global 
pharmaceutical companies. 
Screening Platforms and Technologies 
The approaches used across ASGs are multidisciplinary, yet complimentary: target identification and 
de-risking of potential targets using high throughput functional genomics bridges the often all too 
apparent translational gap between the academic research and drug discovery disciplines [3, 4]. 
Platforms such as RNAi screening can support target identification, while concurrently providing 
novel biological insights.  Moreover, dedicated efforts to unearth novel chemical starting points for 
drug discovery are increasing, supplemented with committed medicinal and/or computational 
chemistry for development of lead compounds. The re-purposing of existing therapeutics is 
increasingly complementing the more traditional drug discovery workflow as more groups begin to 
use screening to explore the potential applications of existing drugs for alternate indications [5]. 
ASGs have also been a main driver for the development and implementation of high-content 
imaging and analysis in drug discovery. We found that amongst UK ASGs which are engaged in cell 
based phenotypic screening; all employ state of the art high content imagers and most employ 
multiple instruments. Other platforms typically perceived to be restricted to use of pharmaceutical 
companies such as acoustic dispensing are now well embedded in ASGs, with a total of 19 Echos 
systems (Labcyte) sited in 14 ASGs.  
Tralau-Stewart et al also reported an apparent lack of uptake of HTS (defined as screening 
collections of >100K compounds) in UK-based ASGs. At the time of their review, both the CRUK 
Cancer Therapeutics Unit at The Institute of Cancer Research and CRT DL were regularly screening 
>100K compounds.  Along with MRCT and DDU Dundee, these centres are fully capable of large-scale 
screening, though it is still not commonplace in ASGs. Given limitations in funding, this will likely 
remain so as it is, arguably, unnecessary to duplicate such efforts. Typically, ASGs use high diversity 
libraries of 10-50K compounds or smaller focussed compound sets. Since the publications of 
Swinney and Anthony [6, 7], highlighting that phenotypic approaches were more successful than 
target-based approaches in identifying first-in-class drugs, there has been a dramatic change in the 
perception of the necessity of screening vast numbers of compounds in order to identify the most 
apposite start points for innovative drug development. The focus has shifted to screening fewer, 
more discrete, well designed and diverse compound libraries. When coupled with advanced 
computational approaches to virtually explore chemical space in silico, it becomes evident that size 
of screening collections is not necessarily the most critical criterion for success in primary HTS [8, 9]. 
 
Discussion 
Screening within an academic environment forms an integral part of drug discovery initiatives within 
the UK, and efforts in this area have undergone dramatic expansion over the last 10 years. 
Furthermore, the strategic alliance between academia, the UK government and the pharmaceutical 
industry is exemplified by i) the £8 million investment into the UK National Phenotypic Screening 
Centre (UKNPSC, 2014), sourced principally from the Scottish Government via the Scottish Funding 
Council with both academia and industry supporting running costs, and ii) the establishment of the 
European Screening Centre, which supports researchers and SMEs in screening around 300K 
compounds, collectively contributed by seven pharmaceutical companies. While sources and 
timescales of funding continue to evolve, the level of investment in the infrastructure and research 
of UK-based ASGs may represent an emerging cultural shift in the recognition of the value of 
academic drug discovery efforts. 
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